KUALA LUMPUR: Apex Healthcare Bhd recorded a net profit of RM14.01mil in the third quarter ended Sept 30, 2021, which was almost on par with the net earnings of RM14.22mil posted in the previous corresponding quarter.

       Revenue for the quarter under review was RM211.06mil, a 24.8% improvement over the comparative quarter due to the significantly higher market demand for pharmaceuticals, diagnostics and consumer healthcare.

       It said in a bourse filing that revenue growth was also helped by robust market demand for pulse oximeters, surgical masks, Covid-19 self-test kits in Malaysia and SinoPharm and SinoVac Covid-19 vaccines in Singapore.

       Over the nine months to Sept 30, Apex posted a net profit of RM38.71mil, 7% lower than in the same period last year.

       Revenue was higher at RM573.1mil, 6.69% improved from RM537.15mil in the comparative period.

       On prospects, the group said it maintains its cautious stance and expects the business environment to stay challenging for the rest of the current financial year and into 2022.

       "Further unforeseen market changes and developments aside, the Group expects to deliver a satisfactory performance for the current financial year," it added.